Current problems in cancer. Case reports最新文献

{"title":"Low-grade B-cell lymphomas in the spinal epidural space: A case series and review of the literature","authors":"Sandra Leskinen ,&nbsp;Hamza Khilji ,&nbsp;Faina Ablyazova ,&nbsp;Avraham Zlochower ,&nbsp;Manju Harshan ,&nbsp;A. Gabriella Wernicke ,&nbsp;Morana Vojnic ,&nbsp;Randy S. D'Amico","doi":"10.1016/j.cpccr.2023.100269","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100269","url":null,"abstract":"<div><p>Lymphoma rarely arises within the central nervous system and occurs most commonly in association with disseminated systemic disease. Primary epidural lymphomas of the spine are infrequently encountered and are usually high-grade, diffuse large B-cell lymphomas. Low-grade lymphomas arising in the spine are rarer than high-grades and are usually marginal zone lymphomas. While treatments for systemic high-grade lymphomas are well defined, treatment of low-grade lymphomas arising within the Dura or within the epidural space are less defined. We present two cases of primary spinal Dural- and epidural-based low-grade lymphomas diagnosed surgically and treated with local adjuvant radiation without chemotherapy. Both patients demonstrated excellent long term symptomatic and systemic disease control. We review the literature on epidural and Dural low-grade lymphomas to guide treatment of these rare lesions.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"12 ","pages":"Article 100269"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621923000534/pdfft?md5=8656c2390c3940dba470d65f9116121a&pid=1-s2.0-S2666621923000534-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138501300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduced-dose carmustine (300 mg/m2) and melphalan as a conditioning regimen in multiple myeloma patients with CNS involvement: A case series","authors":"Garrett Rueda ,&nbsp;Eric Smith ,&nbsp;Nicolas De Padova ,&nbsp;Hayley Heers ,&nbsp;Ivan Komerdelj","doi":"10.1016/j.cpccr.2023.100270","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100270","url":null,"abstract":"<div><p>Single-agent melphalan remains the gold standard for conditioning chemotherapy prior to autologous stem cell transplantation (ASCT) in the multiple myeloma (MM) setting. Melphalan's distribution in the central nervous system (CNS) is limited which raises the question if single-agent melphalan is the ideal conditioning regimen for MM patients with extramedullary involvement in the CNS. Here we present two patients with MM and CNS involvement at baseline who safely received reduced-dose carmustine (300 mg/m²) and melphalan for conditioning chemotherapy prior to ASCT. While this combination has been studied previously, no studies to our knowledge added carmustine to the preparative regimen explicitly for additive CNS penetration in patients with CNS involvement.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"12 ","pages":"Article 100270"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621923000546/pdfft?md5=317ba326557f4aeefc515088e49dcaab&pid=1-s2.0-S2666621923000546-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138480408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nodular hidradenoma of breast skin mimicking metaplastic squamous carcinoma of the breast: A case report","authors":"W. Black ,&nbsp;Y. Fang ,&nbsp;S. Syed","doi":"10.1016/j.cpccr.2023.100268","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100268","url":null,"abstract":"<div><p>Nodular hidradenoma is an uncommon benign skin tumor arising from sweat glands that most commonly present in the head and neck as an indolent protruding cutaneous nodule with external skin changes. More rarely, they may arise in the breast skin with characteristics that may mimic metaplastic carcinoma, resulting in a diagnostic dilemma for physicians. We report a case of breast skin nodular hidradenoma with an unusual presentation and initial concern for invasive metaplastic breast carcinoma on core-needle biopsy. We discuss the diagnostic challenges of this rare breast tumor with recommendations for future diagnostic strategies when concerned for skin-based breast lesions.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"12 ","pages":"Article 100268"},"PeriodicalIF":0.0,"publicationDate":"2023-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621923000522/pdfft?md5=a86fc2f492cf1ad361479052df3ebce7&pid=1-s2.0-S2666621923000522-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary neuroendocrine carcinoma of inguinal lymph node as a plausible entity: A case report","authors":"Jane Rhyu ,&nbsp;Saeed Sadeghi ,&nbsp;Jonathan C. King ,&nbsp;Steven D. Hart ,&nbsp;Jianyu Rao ,&nbsp;Run Yu","doi":"10.1016/j.cpccr.2023.100267","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100267","url":null,"abstract":"<div><p>We report primary neuroendocrine carcinoma (NEC) of the inguinal lymph node (LN) as a plausible clinical entity. Though previously controversial and suspected to alternatively represent an atypical presentation of LN metastasis from an unknown primary, we now report the third case of isolated inguinal LN NEC. The cases strongly support this diagnosis as a separate clinical entity with indolent behavior, unlike NEC that has metastasized to the LN. Our patient was a 68-year-old female who presented with an isolated left 4 cm enlarged inguinal LN. A core needle biopsy of the mass demonstrated cores of soft tissue that were diffusely infiltrated by loosely cohesive neoplastic cells in streaming cords and clusters. The cells were hyperchromatic, enlarged, and exhibited very high nucleus to cytoplasm ratio with prominent nuclear crowding, vesicular chromatin, inconspicuous to rare nucleoli, and scant cytoplasm. Mitotic activity was robust. Immunohistochemistry staining showed positivity for synaptophysin with Ki67 &gt;80 % but was not supportive of lymphoma or Merkel cell carcinoma. The cytological diagnosis was metastatic small cell NEC. FDG-PET/CT showed intense FDG avidity of the left inguinal LN without any evidence of potential primary malignancy or distant metastatic disease. Based on 2 previous case reports with favorable outcomes, we considered primary inguinal LN NEC as a plausible diagnosis. The patient underwent surgical resection with surgical histology confirming small cell NEC in LN, and systemic therapy and radiation therapy were held off. Postoperatively, the patient has remained disease-free for 16 months. Recognition of this clinical entity is important as it carries favorable prognosis with surgery as first line therapy. Primary inguinal LN NEC should be considered in the differential diagnosis of NECs in an inguinal LN.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"12 ","pages":"Article 100267"},"PeriodicalIF":0.0,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621923000510/pdfft?md5=cac9a80b8b9cc214672f525a981974e7&pid=1-s2.0-S2666621923000510-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138390523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testicular seminoma relapse to the adrenal glands 25 years after primary diagnosis: A case report","authors":"Christine Federspiel Secher ,&nbsp;Thomas Wagner ,&nbsp;Anand Chainsukh Loya ,&nbsp;Gedske Daugaard ,&nbsp;Jakob Lauritsen","doi":"10.1016/j.cpccr.2023.100266","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100266","url":null,"abstract":"<div><p>Testicular seminoma is a frequent tumor in young men, and most patients are cured after primary treatment. Relapse of the disease typically occurs within the first two years and late relapse after more than 5 years is only seen in around 4 %. The predominantly site of relapse is the retroperitoneal space, and non-pulmonary metastases such as adrenal metastases are rarely seen. We here report an exceedingly unusual case of seminoma relapse with bilateral adrenal metastases 25 years after diagnosis.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"12 ","pages":"Article 100266"},"PeriodicalIF":0.0,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621923000509/pdfft?md5=cab7ad2c3382d84ca2fdf93c6aa8ac36&pid=1-s2.0-S2666621923000509-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134656525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare type of primary CD19-negative diffuse large B-cell lymphoma presenting as an infraorbital mass in the maxillary sinus","authors":"Nabil El Hage Chehade ,&nbsp;Dina Elantably ,&nbsp;Sara Ghoneim ,&nbsp;Fnu Raja ,&nbsp;Kyle Hunter ,&nbsp;William Tse","doi":"10.1016/j.cpccr.2023.100265","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100265","url":null,"abstract":"<div><p>A 38-year-old male recently diagnosed with acute on chronic rhinosinusitis and orbital cellulitis presented with a right painful infraorbital mass and swelling. Fine needle aspiration of the mass demonstrated atypical lymphoid infiltrate highly suggestive of lymphoma. Flow cytometry and immunophenotypic analysis detected an abnormal lymphocytic population characterized by positive CD20, CD38, and CD10, however, the CD19 marker was negative. Whole-body positron emission tomography showed a sizeable hypermetabolic mass centered at the right maxillary sinus, extending into the right orbit, and several hypermetabolic lymph nodes in the right neck. A diagnosis of high-grade CD19-negative DLBCL was made and the patient was initiated on R-HyperCVAD (Rituximab- cyclophosphamide, vincristine, Adriamycin, dexamethasone) chemotherapy protocol.</p><p>The diagnosis of paranasal lymphoma may remain elusive for months leading to delays in treatment, thus a high index of suspicion is warranted. The loss of CD19 expression in DLBCL represents a diagnostic challenge because this surface marker is widely used to gate the B cells for immunophenotyping and flow cytometry analysis. It also leads to therapeutic limitations to CD19 targeting therapies.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"12 ","pages":"Article 100265"},"PeriodicalIF":0.0,"publicationDate":"2023-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621923000492/pdfft?md5=052c87af88768f431e7873740c6e9ac9&pid=1-s2.0-S2666621923000492-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92073803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of hepatic dysfunction from crizotinib followed by treatment with entrectinib","authors":"Takahito Mizuno ,&nbsp;Satoshi Hagimoto ,&nbsp;Takumi Umemura ,&nbsp;Mariko Higashikawa ,&nbsp;Takamasa Sakai ,&nbsp;Kouichi Tanabe ,&nbsp;Fumiko Ohtsu ,&nbsp;Tetsuya Yamada ,&nbsp;Tomoki Kimura","doi":"10.1016/j.cpccr.2023.100262","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100262","url":null,"abstract":"<div><h3>Background</h3><p>Information regarding the safety of entrectinib for previously treated patients and patients with hepatic dysfunction is limited. This is the first case report of treatment modification attributable to hepatic dysfunction caused by crizotinib.</p></div><div><h3>Patients</h3><p>A 76-year-old Japanese woman was referred to the Department of Respiratory Medicine and Allergy after a computed tomography (CT) scan at the time of thyroid surgery. The CT scan revealed an enlarged right upper lobe nodule. After careful examination, she was diagnosed with T3N2M1c stage IV ROS1-positive lung adenocarcinoma; therefore, crizotinib (500 mg/day) was prescribed. On day 861 of treatment, crizotinib was discontinued because of repeatedly observed increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Approximately 2 weeks after crizotinib was discontinued, treatment was restarted with entrectinib 600 mg/day.</p></div><div><h3>Conclusions</h3><p>Entrectinib was prescribed because crizotinib caused hepatic dysfunction; however, the patient experienced grade 3 neutropenia and the creatinine phosphokinase (CPK) levels increased. After the dose reduction, she was able to continue treatment safely, without further worsening of the primary tumor or hepatic dysfunction. Therefore, entrectinib may be an option for patients who need treatment modification because of crizotinib-induced hepatic dysfunction. Increased CPK is a previously unknown adverse event occurring with entrectinib. This information is essential to risk management plans involving this drug. Further information regarding increased CPK and rhabdomyolysis occurring in patients treated with entrectinib is needed.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"12 ","pages":"Article 100262"},"PeriodicalIF":0.0,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49846525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central nervous system manifestations as initial presentation of plasma cell disorders: Differential management of 3 cases based on disease extent","authors":"Kyle McGrath ,&nbsp;Graeme A. Fenton ,&nbsp;Robert P. Seifert ,&nbsp;Keith R. Peters ,&nbsp;John W. Hiemenz ,&nbsp;Erin A. Dean","doi":"10.1016/j.cpccr.2023.100247","DOIUrl":"10.1016/j.cpccr.2023.100247","url":null,"abstract":"<div><p>Central nervous system (CNS) manifestations of plasma cell neoplasms are exceedingly uncommon. CNS multiple myeloma (MM) carries a dismal prognosis, and limited evidence exists to guide management of these patients. We report on 3 adult patients with plasma cell neoplasms that presented with CNS manifestations. After summarizing their clinical presentation along with radiologic and pathologic findings, we focus on the patients’ differential management depending on extent of disease while reviewing the literature on frontline therapy in this rare disease scenario.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100247"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49354352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis","authors":"Aimee Schad ,&nbsp;Abhinandan R Pakanati ,&nbsp;Susan Woelich ,&nbsp;Abhishek Chilkulwar","doi":"10.1016/j.cpccr.2023.100249","DOIUrl":"10.1016/j.cpccr.2023.100249","url":null,"abstract":"<div><p>Classical Hodgkin Lymphoma (cHL) is a B-cell derived lymphoma with excellent cure rates, however poor functional status or co-morbid conditions limit treatment options. Brentuximab vedotin (BV), a CD30 antibody drug conjugate, has an expanding role in cHL treatment. A 53-year-old man with multiple co-morbidities including end stage renal disease (ESRD) presenting with pancytopenia was found to have cHL. Not a candidate for intensive chemotherapy, he was safely maintained on intermittent BV for three years. Literature on prolonged BV use in hemodialysis is extremely limited. This case suggests BV as a safe treatment option for CD30 positive cHL in patients with ESRD on hemodialysis.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100249"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49373841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Orbital cellulitis and massive chemosis as first sign of a cilio-choroidal malignant melanoma without extraocular extension: A case report","authors":"Matteo Mario Carlà ,&nbsp;Carmela Grazia Caputo ,&nbsp;Maria Grazia Sammarco ,&nbsp;Federico Giannuzzi ,&nbsp;Chiara Fantozzi ,&nbsp;Gustavo Savino ,&nbsp;Maria Antonietta Blasi ,&nbsp;Monica Maria Pagliara","doi":"10.1016/j.cpccr.2023.100253","DOIUrl":"10.1016/j.cpccr.2023.100253","url":null,"abstract":"<div><h3>Purpose</h3><p>To describe a case of cilio-choroidal melanoma presenting as aseptic orbital cellulitis with massive conjunctival chemosis.</p></div><div><h3>Methods</h3><p>Case report.</p></div><div><h3>Results</h3><p>A 51-year-old man with a left retro-iris pigmented lesion had acute lid edema, conjunctival chemosis, and extensive hyphema. Ultrasound revealed a large, lobulated, wide-base choroidal-starting lesion affecting the ciliary bodies and vitreous chamber. MRI revealed low-intermediate T2-signal and intermediate-high T1-signal, with substantial post-contrastographic enhancement. After one week of systemic corticosteroids, the chemosis reduced significantly, and the patient was referred for enucleation, even without histologic confirmation. Post-surgical histopathology found 90% necrotic tissue, few viable cells, and no scleral or vascular invasion, with genetic analysis showing monosomy of chromosome 3 and 8q gain.</p></div><div><h3>Conclusion</h3><p>Choroidal melanoma, particularly if necrotic, may occasionally present as aseptic orbital cellulitis, even without extraocular spread.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"11 ","pages":"Article 100253"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46535821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}